Literature DB >> 25562591

Determinants of patient-rated and clinician-rated illness severity in schizophrenia.

Gagan Fervaha1, Hiroyoshi Takeuchi, Ofer Agid, Jimmy Lee, George Foussias, Gary Remington.   

Abstract

OBJECTIVE: The contribution of specific symptoms on ratings of global illness severity in patients with schizophrenia is not well understood. The present study examined the clinical determinants of clinician and patient ratings of overall illness severity.
METHOD: This study included 1,010 patients with a DSM-IV diagnosis of schizophrenia who participated in the baseline visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study conducted between January 2001 and December 2004 and who had available symptom severity, side effect burden, cognition, and community functioning data. Both clinicians and patients completed the 7-point Clinical Global Impressions-Severity of Illness scale (CGI-S), the primary measure of interest in the present study. Symptoms were rated using the Positive and Negative Syndrome Scale and the Calgary Depression Scale for Schizophrenia, and functional status with the Quality of Life Scale. Neurocognition, insight, and medication-related side effects were also evaluated.
RESULTS: Clinicians rated illness severity significantly higher than patients (P < .001). There was moderate overlap between CGI-S ratings made by clinicians and patients, with almost one third of patients showing substantial (ie, greater than 1 point) discrepancies with clinician ratings. Clinician-rated CGI-S scores were most strongly associated with positive symptoms, with additional independent contributions made by negative, disorganized, and depressive symptoms, as well as functional outcome (all P values < .01). Patient-rated CGI-S scores, on the other hand, were most closely related to depressive symptoms, with additional independent contributions made by positive and anxiety symptoms, clinical insight, and neurocognition (all P values < .01). Depressive symptoms were the strongest predictor of patient-rated CGI-S scores even in patients with good clinical insight (P < .001).
CONCLUSIONS: Patient and clinician views of overall illness severity are not necessarily interchangeable and differ in their clinical correlates. Taking these differences into account may enhance patient engagement in care and improve outcomes. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00014001. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 25562591     DOI: 10.4088/JCP.14m09128

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

1.  Comparative Efficacy and Acceptability of Pharmaceutical Management for Adults With Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis.

Authors:  Zhen-Dong Huang; Yi-Fan Zhao; Shuang Li; Hui-Yun Gu; Lu-Lu Lin; Zhi-Yan Yang; Yu-Ming Niu; Chao Zhang; Jie Luo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

2.  Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression.

Authors:  Meredith Blampied; Caroline Bell; Claire Gilbert; Joseph Boden; Rebecca Nicholls; Julia J Rucklidge
Journal:  Medicines (Basel)       Date:  2018-06-14

3.  The latent structure of depressive symptoms across clinical high risk and chronic phases of psychotic illness.

Authors:  Teresa Vargas; Anthony O Ahmed; Gregory P Strauss; Cassandra M Brandes; Elaine F Walker; Robert W Buchanan; James M Gold; Vijay A Mittal
Journal:  Transl Psychiatry       Date:  2019-09-16       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.